Mr. Daniel E. Geffken is a CFO, Principal Financial & Accounting Officer at OPY Acquisition Corp. I, a Chief Financial Officer at Phoenix Biotech Acquisition Corp., a Chief Financial & Accounting Officer at Eloxx Pharmaceuticals, Inc., a Chief Financial Officer at CalciMedica, Inc., a Chief Financial Officer at DermBiont, Inc., a Chief Financial Officer at Palvella Therapeutics, Inc., a Chief Financial Officer at Privo Technologies, Inc., a Chief Financial Officer at Zikani Therapeutics, Inc., an Independent Director at Windtree Therapeutics, Inc., a Chief Financial Officer at Apic Bio, Inc., a Chief Financial Officer at Vigeo Therapeutics, Inc., a Chief Financial Officer at ProMIS Neurosciences, Inc., a Chief Financial Officer at Antolrx, Inc., a Chief Financial Officer & Director at Elicio Therapeutics, Inc., a Co-Managing Director at Danforth Advisors LLC, a Chief Financial Officer at Artax Biopharma, Inc., a Chief Financial Officer at Clear Creek Bio, Inc., a Chief Financial Officer at GenePeeks, Inc., a Chief Financial Officer at Matrivax Research & Development Corp., a Chief Financial Officer at Myeloid Therapeutics, Inc., a Chief Financial Officer at Nemucore Medical Innovations, Inc., a Chief Financial Officer at Prilenia Therapeutics Development Ltd., a Chief Financial Officer at United Neuroscience Ltd., a Chief Financial Officer at Vaxxinity, Inc. and a Chief Financial Officer at Windgap Medical, Inc.

He is on the Board of Directors at Windtree Therapeutics, Inc., Elicio Therapeutics, Inc. and SG DAN Holdings LLC. Mr. Geffken was previously employed as a Chief Financial Officer by Locust Walk Acquisition Corp., a Chief Financial Officer by Cabaletta Bio, Inc., an Independent Director by Arcturus Therapeutics Ltd., a Chief Financial Officer by Stealth BioTherapeutics Corp., a Chief Financial Officer by Apellis Pharmaceuticals, Inc.,